BioCryst Pharmaceuticals | BCRX - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
Chugai Pharma JPY 29.04B 143M 2026-06
Daiichi Sankyo JPY 249.96B 21.73B 2026-06
DBV Technologies USD 13.4M 8.14M 2026-03
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.19B 75M 2026-06
Glaxosmithkline GBP 2.12B 1.44B 2026-03
Incyte USD 351.73M 23.64M 2026-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Karyopharm Therapeutics USD 10.42M 861K 2026-03
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novavax USD 25.53M 1.34M 2025-12
PTC Therapeutics USD 73.89M 13.31M 2026-03
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06